Regencell Bioscience Holdings Limited

NasdaqCM RGC

Regencell Bioscience Holdings Limited Free Cash Flow Yield on December 05, 2024

Regencell Bioscience Holdings Limited Free Cash Flow Yield is NA on December 05, 2024, a NA change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

Regencell Bioscience Holdings Limited 52-week high Free Cash Flow Yield is NA on December 05, 2024, which is NA below the current Free Cash Flow Yield.
Regencell Bioscience Holdings Limited 52-week low Free Cash Flow Yield is NA on December 05, 2024, which is NA below the current Free Cash Flow Yield.
Regencell Bioscience Holdings Limited average Free Cash Flow Yield for the last 52 weeks is NA.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

NasdaqCM: RGC

Regencell Bioscience Holdings Limited

CEO	Mr. Yat-Gai Au
IPO Date	July 16, 2021
Location	Hong Kong
Headquarters	First Commercial Building
Employees	12
Sector	Health Care
Industries Biotechnology Pharmaceuticals Research & Consulting

Description

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

Key trends

Past 5 years